First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

By J. Tabernero, G. Shapiro, P. LoRusso, A. Cervantes, G. Schwartz, G. Weiss, L. Paz-Ares, D. Cho, J. Infante, M. Alsina and 18 more. Cancer Discovery, 2013

661 citations recorded by the source corpus.

Subfields: Biomaterials, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/360d361326a1d55e44d1ecadc2c0fc14ea289087

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Molecular Biology

Citations in the corpus

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Other clinical evidences of RNA interference have been obtained since then [3].”
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge (2019, background): “siRNA can precisely and effectively silence targeted genes [30].”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “The antitumor efficacy ofVEGF and KSP siRNA liposomes was also observed in a clinical study in which 1 patient attained a complete response for over 26 months and 3 patients achieved stable disease at all anatomic sites for ;8–12 months (Tabernero et al., 2013). b.”
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine (2017, background): “It is used for the management of advanced solid liver tumors (mainly primary and secondary liver cancers).(38) Lipid nanoparticles (LNPs) can efficiently deliver siRNAs to cellular targets.”
Cancer Nanomedicine: From Targeted Delivery to Combination Therapy (2015, background): “In addition, a multiple siRNA combination therapy recently demonstrated increased efficacy in phase I clinical trials [74].”